NATIONAL TAIWAN UNIVERSITY HOSPITAL

• JelloX Biotech's 3D pathology technology identified significantly more HER2-low and HER2-ultralow breast tumors compared to conventional diagnostic methods in a study with National Taiwan University Hospital. • Over 50% of analyzed breast cancer cases showed diagnostic discrepancies when re-evaluated with 3D pathology, with 66.7% of initially HER2-null patients reclassified as HER2-expressing. • The improved detection sensitivity could expand treatment eligibility for Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that has shown robust efficacy in HER2-low and HER2-ultralow metastatic breast cancer.

Ainos has secured TFDA approval for a clinical trial of VELDONA in HIV-related oral warts and IRB clearance for a Sjögren's Syndrome study, targeting two rare diseases with significant unmet needs.

Volition has enrolled the first patient in a 500-patient validation study at National Taiwan University Hospital to evaluate Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in LDCT lung cancer screening.

Taiwanese researchers from NTHU and NHRI have developed a breakthrough small-molecule drug that treats chronic intestinal inflammation by blocking PANX1 ion channels in intestinal cells.